US biopharmaceutical company Pfizer Inc (NYSE:PFE) announced on Wednesday that it has entered into an exclusive licensing agreement with biotechnology company Starna Therapeutics to develop and commercialise three preclinical in vivo chimeric antigen receptor T-cell (CAR-T) programmes targeting autoimmune diseases outside Greater China.
The agreement also grants Pfizer rights to use Starna's proprietary in vivo CAR-T technology in inflammation and immunology, as well as oncology.
Starna will receive an upfront payment of USD330m and is eligible for up to USD2.3bn in development and commercial milestone payments, in addition to royalties on net sales of approved products. Pfizer will lead clinical development outside Greater China and manufacture finished drug products for initial clinical trials at its US facilities.
Pfizer will retain exclusive commercialisation rights outside Greater China and hold options to expand its licensing territory to include the region. The agreement also provides options to exclusively license compounds developed under a separate research collaboration.
The deal expands Pfizer's Inflammation and Immunology pipeline, leveraging its expertise in RNA delivery, immunology research, clinical development and commercialisation to advance next-generation cell therapies for autoimmune diseases and cancer.
Inhibrx updates clinical data for ozekibart (INBRX-109) in Ewing sarcoma
Onward Therapeutics closes Series B financing
Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial
Apotex launches generic version of INLYTA in US market
Akeso submits sNDA for ivonescimab chemotherapy combination in first-line biliary tract cancer
Specialised Therapeutics' YONDELIS sarcoma therapy approved in Thailand
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism